DURHAM, N.C.--(BUSINESS WIRE)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today an update in its dry eye program. Inspire provided additional information to the U.S. Food and Drug Administration (FDA) in November 2006 related to Prolacria(TM) (the proposed U.S. trade name for diquafosol tetrasodium ophthalmic solution 2%). Inspire has been granted a meeting with the FDA to continue discussions regarding Inspire’s dry eye clinical program and expects to provide an update on this program by the end of February 2007.
